Immix Biopharma (NASDAQ:IMMX – Get Free Report) will likely be announcing its Q3 2026 resultson Friday, November 6th. Analysts expect Immix Biopharma to post earnings of ($0.18) per share for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Tuesday, November 10, 2026 at 4:00 PM ET.
Immix Biopharma (NASDAQ:IMMX – Get Free Report) last issued its earnings results on Friday, August 7th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.01). On average, analysts expect Immix Biopharma to post ($0.76) EPS for the current fiscal year and ($0.86) EPS for the next fiscal year.
Immix Biopharma Trading Down 1.8%
Shares of IMMX stock opened at $7.98 on Friday. Immix Biopharma has a 1-year low of $2.85 and a 1-year high of $15.10. The company has a market capitalization of $570.89 million, a price-to-earnings ratio of -9.07 and a beta of 0.24. The stock’s fifty day simple moving average is $11.13 and its 200-day simple moving average is $9.42.
Analyst Ratings Changes
View Our Latest Research Report on Immix Biopharma
About Immix Biopharma
Immix Biopharma, Inc is a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with difficult-to-treat cancers and other serious diseases. The company’s research and development activities are centered on engineered immune-cell treatments intended to target malignant cells.
Its lead product candidate is NXC-201, an investigational autologous chimeric antigen receptor T-cell (CAR-T) therapy designed to target B-cell maturation antigen (BCMA). NXC-201 is being evaluated in clinical studies for relapsed or refractory multiple myeloma and relapsed or refractory AL amyloidosis, a rare blood disorder in which abnormal plasma cells produce misfolded proteins.
Immix Biopharma was founded in 2012 and is headquartered in Los Angeles, California.
Featured Stories
- Five stocks we like better than Immix Biopharma
- Phillips 66 Posts Strong Earnings But the Stock Doesn’t Care
- NXP Semiconductors Falls After Strong Earnings—Is the Sell-Off Overdone?
- GE Vernova’s Reservations Are Turning Into Real Orders—But the Market Still Wants More.
- Where’s the Beef? Trian-Led Buyout Proposal Values Wendy’s at $1.4B, But Is It Enough?
Receive News & Ratings for Immix Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immix Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
